University of California, Los Angeles CARE Center CRS

Location	1399 S. Roxbury Drive, Suite 100 Los Angeles, CA 90035 United States of America
Phone	310-557-3759
CRS Coordinator	Aleen Khodabakhshian akhodabakhshian@mednet.ucla.edu 310-557-9640
CRS Leader	Raphael Landovitz rlandovitz@mednet.ucla.edu 310-825-3782
Studies	A5128: US Genomic Sampling A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5332: REPRIEVE Trial A5354: Early ART in Acute HIV A5355: Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function A5357: A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1 A5359: The LATITUDE Study A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B A5386: N-803 with or without bNAbs for HIV-1 control in participants living with HIV-1 on suppressive ART A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies A5418:Study of Tecovirimat for Human Monkeypox Virus (STOMP) ACTG A5383: Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT) A5392: Pharmacokinetic Interactions of Etonogestrel (ENG) Subdermal Implants with Long-Acting (LA) Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA) in Participants of Reproductive Potential